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Abstract
Mitochondrial dysfunction is one of the pathogenic mechanisms that lead to neurodegeneration in Amyotrophic Lateral Sclerosis
(ALS). Astrocytes expressing the ALS-linked SOD1
G93A mutation display a decreased mitochondrial respiratory capacity associated
to phenotypic changes that cause them to induce motor neuron death. Astrocyte-mediated toxicity can be prevented by
mitochondria-targeted antioxidants, indicating a critical role of mitochondria in the neurotoxic phenotype. However, it is presently
unknown whether drugs currently used to stimulate mitochondrial metabolism can also modulate ALS progression. Here, we
tested the disease-modifying effect of dichloroacetate (DCA), an orphan drug that improves the functional status of mitochondria
through the stimulation of the pyruvate dehydrogenase complex activity (PDH). Applied to astrocyte cultures isolated from rats
expressing the SOD1
G93A mutation, DCA reduced phosphorylation of PDH and improved mitochondrial coupling as expressed by
the respiratory control ratio (RCR). Notably, DCA completely prevented the toxicity of SOD1
G93A astrocytes to motor neurons in
coculture conditions. Chronic administration of DCA (500 mg/L) in the drinking water of mice expressing the SOD1
G93A mutation
increased survival by 2 weeks compared to untreated mice. Systemic DCA also normalized the reduced RCR value measured in
lumbar spinal cord tissue of diseased SOD1
G93A mice. A remarkable effect of DCA was the improvement of grip strength
performance at the end stage of the disease, which correlated with a recovery of the neuromuscular junction area in extensor
digitorum longus muscles. Systemic DCA also decreased astrocyte reactivity andp r e v e n t e dm o t o rn e u r o nl o s si nS O D 1
G93A mice.
Taken together, our results indicate that improvement of the mitochondrial redox status by DCA leads to a disease-modifying
effect, further supporting the therapeutic potential of mitochondria-targeted drugs in ALS.
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Introduction
ALS is a fatal paralytic neurodegenerative disease characterized
by motor neuron loss, which leads to death within 3–5 years of
diagnosis. No therapy is available other than riluzole, which
extends the lifespan of patients by only 3–6 months [1].
Mitochondrial dysfunction can contribute to motor neuron
degeneration in ALS and description of mitochondrial alterations
have been fully documented in the spinal cord and the muscle
from patients and animal models linked to SOD mutations (for
review see [2,3]). Astrocytes from rats expressing SOD1
G93A
display reduced mitochondrial ability to synthesize ATP and
produce increased levels of nitric oxide [4], superoxide and
peroxynitrite [5] and accordingly, these effects can be reverted
with mitochondria-targeted antioxidants [5]. Interestingly, mito-
chondrial dysfunction in astrocytes is associated to neurotoxic
phenotypic changes that reduce motor neuron survival [5].
Astrocytes surrounding motor neurons are known to modulate
ALS progression. Indeed, analyses of chimeric mice composed of
mixtures of normal and mutated SOD1–expressing cells have
offered evidence that motor neuron death is non–cell-autonomous
[6]. Restricted mutated SOD1 expression in astrocytes is not
sufficient for disease development [7]. However, selective
reduction of mutated SOD1 in astrocytes increases disease
duration after onset as determined by mating mice expressing
mutated SOD1 transgenes flanked by lox sites to mice carrying a
Cre-encoding sequence under control of the promoter from GFAP
[8]. This is accompanied by delayed microglial activation, in
accordance with studies using the same technology for microglia
[9]. Damage induced by mutated SOD1 in astrocytes determines a
phenotype that is neurotoxic for motor neurons in culture and
may account for the role of astrocytes in disease progression
[4,10,11]. Indeed, the recent isolation of astrocytes with aberrant
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cultures of symptomatic SOD1
G93A rats with unprecedented
proliferative and neurotoxic capacity [12] further supports a role
for astrocytes in ALS progression. It remains to be determined
whether the neurotoxic phenotype of SOD1
G93A-expressing
astrocytes may be reverted by the improvement of mitochondrial
metabolism and in turn slow disease progression.
The organohalide dichloroacetate (DCA) is a well-characterized
inhibitor of the protein kinase of the pyruvate dehydrogenase
(PDH) [13]. PDH, located in the mitochondrial matrix, in its
active unphosphorylated state mediates acetyl coenzyme-A
formation from pyruvate, which feeds the electron transport chain
responsible for ATP synthesis and oxygen consumption. Phos-
phorylation of PDH by PDH kinase (PDK) generates its inactive
phosphorylated state. DCA-mediated inhibition of PDK renders
most of PDH in the active form and then pyruvate metabolism
switches towards glucose oxidation to CO2 in the mitochondria
(Fig. 1). Another mechanism by which DCA may favor PDH
activity is to decrease degradation of the E1 alpha subunit of the
complex. It has been claimed that changes in E1 alpha subunit
phosphorylation could affect susceptibility to proteases that may
lead to an increase in the amount of the total enzyme [14].
In the central nervous system, DCA enhances glucose and
lactate oxidation to CO2 and reduces lactate release mainly in
astrocytes compared to having almost no effects on neurons, which
supports the compartmentalization of glucose metabolism between
astroglia and neurons [15]. The fraction of total PDH in the
inactive phosphorylated form is normally greater in astroglia than
in neurons, a situation that favors lactate export from astroglia to
neurons but it can be modulated by DCA [15]. DCA
administration in vivo activates brain PDH activity [16], indicating
that it crosses the blood-brain barrier, and DCA is currently used
clinically to lower elevated lactate levels in cerebrospinal fluid of
patients with mitochondrial disorders [17,18]. However, it is
unknown whether DCA may offer benefits in neurological
disorders associated to mitochondrial dysfunction. Specifically, it
is not known whether DCA may prevent the in vivo and in vitro
neurotoxic influence of SOD1
G93A astrocytes in ALS models by
regulating their mitochondrial respiration.
Here we provide evidence that DCA reduced astrocyte neu-
rotoxicity to motor neurons in culture and furthermore, applied to
ALS mice, slowed disease progression and enhanced motor
strength.
Results
Effect of DCA on SOD1
G93A astrocytes
To evaluate the effects of DCA on PDH we exposed cultures of
SOD1
G93A astrocytes to DCA (5 mM, 24 h) and total and
phosphorylated forms of PDH were quantified by western blotting
assay using specific antibodies (anti PDH-E1a subunit and anti
PDH-E1a-pSer
293 respectively). As expected, exposure of both
non-transgenic (non Tg) and SOD1
G93A astrocytes to DCA
reduced phosphorylated PDH relative levels (Fig. 2A–B). Howev-
er, this effect was greater in SOD1
G93A astrocytes than in non Tg
ones. DCA also increased total levels of PDH in non Tg astrocytes
according to previous reports [14]. Total PDH levels were basally
increased in SOD1
G93A untreated astrocytes.
DCA treatment improved mitochondrial coupling in
SOD1
G93A astrocytes as determined by high-resolution respirom-
etry expressed by the respiratory control ratio (RCR). The RCR
value calculated for untreated SOD1
G93A astrocytes was signifi-
cantly reduced (by 45%) compared to non Tg astrocytes as
described previously [5]. DCA-treated SOD1
G93A astrocytes
showed a significant increase in the RCR to the level of that
shown by non Tg astrocytes (Fig. 2C). We observed that DCA also
reduced the proliferation rate in SOD1
G93A astrocytes that was
otherwise increased by 100% with respect to non Tg ones
(Fig. 2D).
DCA prevented the toxicity of SOD1
G93A astrocytes to
motor neurons
SOD1
G93A astrocytes display neurotoxic influence for motor
neurons in culture, which can be reverted by mitochondria-
targeted antioxidants [5]. In order to elucidate whether improving
mitochondrial function with DCA in SOD1
G93A astrocytes was
also beneficial for motor neuron survival we plated purified motor
neurons on top of DCA-pretreated (0.5–5 mM, 24 h) SOD1
G93A
astrocyte monolayers. This treatment significantly increased motor
neuron survival grown on top of SOD1
G93A astrocytes to the level
of that shown by non Tg astrocytes (Fig. 3).
DCA increased survival of SOD1
G93A mice
To assess whether DCA could also exert protective effects on
the progressive paralysis in SOD1
G93A mice, the compound was
administered from 70 days of age until death in the drinking water
(500 mg/L) as previously described in an animal model of
Huntington’s disease [19]. DCA was well tolerated and did not
show apparent signs of intoxication, such as weight loss, disease or
premature death, when compared to non-treated SOD1
G93A and
non Tg control mice. Treatment with DCA significantly increased
survival both in males and females as compared with control mice
treated with water only (males ctrl n=9: 126.962.6 days, DCA
n=9: 138.062.8 days; females ctrl n=10: 130.061.87 days DCA
n=9: 138.462.42 days; Fig. 4A, B). Disease onset was not
significantly affected by DCA (males ctrl n=7: 99.463.0 days;
DCA n=6: 106.262.3 days; females ctrl n=5: 104.2 days65.1;
DCA n=8: 111.366.7 days).
DCA improved motor performance and maintained
motor unit integrity in SOD1
G93A mice
ALS is characterized by progressive muscle weakness and
paralysis. Therefore, we sought to determine the effect of DCA on
motor performance of SOD1
G93A mice. Notably, DCA signifi-
Figure 1. Site of action of dichloroacetate. DCA inhibits the
mitochondrial enzyme PDH kinase, thereby maintaining the PDH
complex in its unphosphorylated catalytically active state and
facilitating the aerobic oxidation of glucose.
doi:10.1371/journal.pone.0034776.g001
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disease (from 100 days of age onward) in male mice compared to
control transgenic ones (Fig. 5A). Grip strength did not improve in
females (data not shown). Because there is a correlation between
the number of active motor units and the force produced by a
muscle, we decided to observe the neuromuscular junction (NMJ)
morphology of two muscles with different fiber composition,
extensor digitorum longus (EDL) and soleus. The NMJs of EDL
muscle in DCA-treated mice displayed normal size (measured as
total area) and shape, which is in agreement with the improvement
of grip strength (Fig. 5B). In control SOD1
G93A mice, the receptor
area decreased in size, as did the spaces between synaptic regions,
leading to an overall compaction of the junction. A 20-day DCA
treatment from 70 days of age onward showed a significant
increase in junction area in EDL muscles compared with
untreated mice. Neuromuscular junctions in soleus muscles did
not show significant improvements with DCA treatment (data not
shown).
DCA treatment improved mitochondrial function in the
spinal cord of SOD1
G93A mice
To assess whether DCA improved mitochondrial function in
vivo, high-resolution respirometry was monitored in mechanically
dissociated spinal cords obtained from mice after 20 days of DCA
administration (from 70 days of age). The RCR value calculated
for untreated SOD1
G93A mice spinal cords was significantly
reduced compared to non Tg littermates according to previous
reports [20]. In contrast, DCA-treated SOD1
G93A mice showed a
significant increase in the RCR compared to the untreated group
(Fig. 6).
DCA reduced motor neuron loss and astrocyte reactivity
in the spinal cord of SOD1
G93A mice
We sought to determine the effect of DCA administration in the
loss of motor neurons in the spinal cord. We noted the already
described reduced motor neuron somas at lumbar spinal segments
Figure 2. DCA recovers mitochondrial respiration rate and controls proliferation in SOD1
G93A astrocytes. A) Representative
immunoblot for PDH-E1a(pSer
293), total PDH-E1a, and b-actin of lysates from non Tg and SOD1
G93A astrocytes after 24 h treatment with DCA or
vehicle as described in Methods. B) Quantification of the PDH-E1a(pSer
293) to total PDH-E1a ratio between relative densitometric levels normalized
against vehicle-treated non Tg astrocytes. C) Calculated respiratory control ratio (RCR) for mitochondria from non Tg or SOD1
G93A-bearing astrocytes
treated with DCA or vehicle as indicated. D) Percentage of BrdU immunoreactive nuclei of non Tg and SOD1
G93A astrocytes after 24 h treatment with
DCA. Data for panels B, C, and D are expressed as mean 6 SEM from three independent experiments performed in duplicate. *p,0.05, significantly
different from non Tg control. **p,0.05, significantly different from SOD1
G93A control.
doi:10.1371/journal.pone.0034776.g002
Figure 3. DCA prevents SOD1
G93A astrocyte neurotoxicity to
motor neurons. Motor neuron survival 72 h after plating either on
non Tg or SOD1
G93A-bearing astrocytes pretreated with DCA or vehicle
as indicated. Data are expressed as percentage of non Tg control, mean
6 SEM from four independent experiments. *p,0.05, significantly
different from non Tg control. **p,0.05, significantly different from
SOD1
G93A control.
doi:10.1371/journal.pone.0034776.g003
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G93A mice when compared to non Tg littermates
(Fig. 7 left column). DCA treatment rescued 25% of motor
neurons at the lumbar level (Rexed lamina IX). In addition, we
assayed astrocytic GFAP immunoreactivity in the spinal cord as a
cellular element contributing to disease progression [8]. Astrocyte
reactivity as determined by GFAP immunofluorescence was
increased in the SOD1
G93A mice in contrast to non Tg littermates
as previously described [21,22]. DCA treatment induced a marked
reduction (70%) in GFAP immunoreactivity in the spinal cord,
when compared to the vehicle-treated group (Fig. 7 right column).
Discussion
It is intriguing that rat [4], mouse [10,11] and also human [23]
astrocytes expressing mutated SOD1 exert toxic effects on motor
neurons. Here, we report that DCA was sufficient to reverse
mitochondrial dysfunction in astrocytes from SOD1
G93A rats and,
at the same time, the phenotypic features that make astrocytes
toxic for motor neurons. Significantly, we provide convincing
Figure 4. DCA increases mean survival of SOD1
G93A transgenic mice. Kaplan-Meyer survival curves from DCA-treated and control SOD1
G93A
male (A) and female (B) mice. DCA was administered in drinking water from 70 days of age until death as detailed in materials and methods. 9 animals
per group, p,0.05, Kaplan-Meyer log-rank test.
doi:10.1371/journal.pone.0034776.g004
Figure 5. DCA delays loss of grip strength and neuromuscular
junction shrinkage in SOD1
G93A mice. A) Hind-limb grip strength
records from non Tg or SOD1
G93A male mice treated with DCA or
vehicle as indicated. DCA-treated non Tg animals did not show
differences with control ones and data are not shown in order to
simplify the graph. Data are mean 6 SEM from 9 animals per group.
*p,0.05, significantly different from SOD1
G93A control. B) ACh receptors
labeled with TMR-BgTx in representative EDL neuromuscular junctions
from non Tg (top), SOD1
G93A control (middle) or DCA-treated SOD1
G93A
(bottom). Quantification of total TMR-BgTx-stained neuromuscular area
in the different groups of animals. Data are expressed as percentage of
non Tg control, mean 6 SEM from 15–35 neuromuscular junctions from
2–4 animals per group. *p,0.05, significantly different from non Tg
control. **p,0.05, significantly different from SOD1
G93A control. Scale
bar: 30 mm.
doi:10.1371/journal.pone.0034776.g005
Figure 6. DCA improves mitochondrial function in the spinal
cord of SOD1
G93A mice. Calculated respiratory control ratio (RCR) for
spinal cord mitochondria from non Tg or SOD1
G93A mice treated with
DCA or vehicle as indicated. Data are mean 6 SEM from three
independent experiments. *p,0.05, significantly different from non Tg
control. **p,0.05, significantly different from SOD1
G93A control.
doi:10.1371/journal.pone.0034776.g006
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astrocytosis, motor neuron death and prolongs motor performance
and survival of SOD1
G93A ALS mice. Since DCA has been used in
humans for decades in the treatment of lactic acidosis and
inherited mitochondrial diseases [18], these results suggest that
DCA may be employed in clinical trials for ALS.
How DCA attenuates the damage induced by the expression of
mutated SOD1 in astrocytes still needs to be clarified. Mitochon-
dria represent a specific site of mutated SOD1 accumulation. In
particular, it accumulates in the outer membrane and the
intermembrane space, where it induces mitochondrial damage
and metabolic dysfunction [3,5]. Oxidative stress to astrocyte
mitochondria may underlie the transformation to a neurotoxic
phenotype [5,24]. Reactive oxygen species (ROS) produced in
mitochondria may affect signal transduction pathways through
oxidation/reduction of cysteine residues in kinases, phosphatases,
and other regulatory factors [25] leading to different, even
opposite cellular responses. By stimulating pyruvate consumption,
DCA improves the redox balance of mitochondria, which may
result in normalization of altered mitochondria-regulated signaling
[26]. Furthermore, DCA applied to mice at doses similar to the
ones we have used but for a longer period of time significantly
induced antioxidant enzyme activities, including superoxide
dismutase, catalase and glutathione peroxidase [27], suggesting
an indirect antioxidant effect of DCA.
Interestingly, DCA beneficial effects on survival and motor
performance were more pronounced in males than in females.
Similar results have been described in previous studies where
different approaches resulted in beneficial effects only in males
[28]. Men have higher risk of suffering ALS than women [29], and
sex differences have also been reported in SOD1
G93A mutant rats
[30] and mice [31–34] particularly when large numbers of animals
are compared [35]. These observations suggest that gender
differences may be partially a result of sex hormone action and in
fact estrogen modulates disease progression in SOD1
G93A mice
[36,37]. Among the various neuroprotective mechanisms proposed
for estrogen actions, the ability to modulate mitochondrial function
[38] and oxidative stress is particularly interesting in this context.
Furthermore, the fact that increased ROS levels were observed in
SOD1
G93A males but not in females [28] suggests that in the latter the
redox balance between pro- and anti-oxidant mechanisms is already
shifted toward neuroprotection, masking DCA beneficial effects.
Previous works have suggested an alteration of mitochondrial
redox metabolism in ALS. Indeed, recent metabolomic analysis of
cerebrospinal fluid [39] or serum [40] by
(1)H NMR spectroscopy
in ALS patients, revealed abnormal metabolite patterns that may
indicate perturbation of glucose metabolism. Among the ap-
proaches that aim to restore mitochondrial function and energy
production, pyruvate administration to ALS mice has been
assessed [41,42]. However, results were contradictory probably
due to differences in doses and animal strains. Nonetheless,
pharmacological administration of DCA did improve mitochon-
drial function underscoring the potential of metabolic modulation
to neutralize the progression of the disease.
In addition to mitochondrial dysfunction, SOD1
G93A astrocytes
also exhibited an increased proliferation rate. Although these two
events might seem unconnected, evidence obtained in cancer cells
indicates that in fact they are mutually related. Otto Warburg in
the 1920s described that increased proliferation rate in cancer cells
is associated to glycolytic metabolism rather than to mitochondrial
oxidation of pyruvate [43]. In accordance, DCA reverses the
glycolytic metabolism in several cancer cell lines along with
reduced proliferation [44]. Our data showing that DCA treatment
of SOD1
G93A astrocytes improved mitochondrial function and
Figure 7. DCA reduces motor neuron loss and astrocyte
reactivity in the spinal cord of SOD1
G93A mice. Representative
Toluidine blue stain (left column) and GFAP immunofluorescence (red,
right column) in anterior horn spinal cord sections from non Tg (top),
SOD1
G93A control (middle) or DCA-treated SOD1
G93A (bottom) mice.
Dotted lines in right column panels indicate the limit between grey and
white matter. The graphs indicate the number of neuronal somas
located in Rexed lamina IX (left) and the percentage of GFAP
immunoreactive area in the ventral horn (right) in the indicated groups
of animals. The corresponding measurement areas are drawn in the top.
Data are mean 6 SEM from at least three animals per group as
indicated in Methods. *p,0.05, significantly different from non Tg
control, **p,0.05, significantly different from SOD1
G93A control. Scale
bars: 50 mm.
doi:10.1371/journal.pone.0034776.g007
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of transduction pathways between cancer cells and SOD1
G93A
astrocytes. Moreover, we have found evidence of unregulated
proliferation and lack of replicative senescence in a population of
phenotypically aberrant astrocytes isolated from SOD1
G93A rats
[12]. Thus, the possibility exists that chronic mitochondrial
dysfunction in neonatal astrocytes promotes long term changes
in astrocyte phenotype and their neurotoxic potential. Although
not analyzed in our study, several cellular pathways might mediate
the increased proliferation rate of SOD1
G93A astrocytes. Among
them we can include up-regulation of the isoform A of the lactate
dehydrogenase (LDH-A) [45], activation of E3 ubiquitin ligase
APC/C-Cdh1 [46], or modulation of transduction pathways by
depolarized mitochondria [47].
Systemic DCA likely improves mitochondrial status in several
other cell types relevant to ALS, including neurons and skeletal
muscle. In the central nervous system, astrocytes seem to
preferentially respond to DCA due to having a greater fraction of
total PDH in the inactive phosphorylated form than neurons [15].
DCA might also exert a direct effect on skeletal muscle. It is
interesting to note that DCA-treated animals remained with
increased grip strength until death compared to untreated animals.
Noticeably, the EDL muscle fibers of DCA-treated mice displayed
neuromuscular junctions with normal size and shape, suggesting
DCA could delay the progressive neuromuscular junction destruc-
tion characteristic of animals with ALS [48]. Furthermore, DCA has
been effective in recovering the function of ischemic muscle [49],
suggesting an effect stimulating muscle trophism or decreasing
deleterious inflammation.
The present study supports the potential use of DCA in multi-
drug approaches to treat ALS. DCA has been also shown to be
protective in models of Huntington’s disease, which also involves
non-cell-autonomous mechanisms [19], suggesting a more general
effect in neurodegenerative diseases. Taken together these data
raise the possibility that DCA might have therapeutic benefits in
ALS patients.
Materials and Methods
Materials
Culture media and serum were obtained from Invitrogen
(Carlsbad, CA). All other reagents were from Sigma Chemical Co
(Saint Louis, MO) unless otherwise specified.
Ethics Statement
Procedures using laboratory animals were in accordance with
international guidelines and were approved by the Institutional
Animal Committee (Comisio ´n honoraria de experimentacio ´n
animal de la Universidad de la Repu ´blica http://www.chea.csic.
edu.uy; CHEA).
Animals
Transgenic ALS mice carrying the G93A mutation for human
SOD1, strain B6SJL-TgN(SOD1-G93A)1Gur [50], were obtained
from Jackson Laboratories (Bar Harbor, ME, USA) and genotyped
as previously described [51]. Mice were housed under controlled
conditions with free access to food and water. Sprague-Dawley
NTac:SD-TgN(SOD1G93A)L26H rats were obtained from Ta-
conic (Hudson, NY; [52]) and were bred locally by crossing with
wild-type Sprague-Dawley female rats.
Dichloroacetate treatment trial
Male and female transgenic mice and non-transgenic littermates
were divided randomly into the following groups (n=9 per group):
A) transgenic control and B) non-transgenic control groups which
received regular drinking water; C) transgenic DCA treatment and
D) non-transgenic DCA treatment groups, administered with
dichloroacetate (DCA; Sigma, St. Louis, MO). DCA was added to
tap water in a 500 mg/L concentration and placed into water
bottles. A daily dose of 100 mg/kg was used based on a daily water
intake of 5 ml. The DCA solution was made fresh twice a week,
with the total consumed volume measured in order to ensure a
constant dose.
The treatment was performed from presymptomatic stage (70
days old) to death. Animals were observed weekly for onset of
disease symptoms, as well as progression to death. Onset of disease
was scored as the first observation of abnormal gait or overt hind
limb weakness. End-stage of the disease was scored as complete
paralysis of both hind limbs and the inability of the animals to
right themselves after being placed on their side.
Cell cultures
Astrocyte cultures: Primary rat spinal cord astrocyte cultures
were prepared from transgenic SOD1
G93A and non-transgenic 1-
day-old pups, genotyped by PCR, as previously described [4,53].
Briefly, cells were plated at a density of 2610
4 cells/cm
2 in 35 mm
Petri dishes or 24-well plates (Nunc, Naperville, IL, USA) and
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), HEPES (3.6 g/
L), penicillin (100 IU/mL) and streptomycin (100 mg/mL).
Astrocyte monolayers were .98% pure as determined by GFAP
immunoreactivity.
Astrocyte-motor neuron cocultures: motor neuron preparations
were obtained from embryonic day 15 (E15) rat spinal cord by a
combination of optiprep (1:10 in L15 medium, SIGMA St. Louis,
MO) gradient centrifugation and immunopanning with the
monoclonal antibody IgG192 against p75 neurotrophin receptor
as previously described [53], then plated on rat astrocyte
monolayers at a density of 300 cells/cm
2 and maintained for
48 h in L15 supplemented medium as described [53].
Treatment of cultures and motor neuron counting
Confluent astrocyte monolayers were changed to L15 supple-
mented media prior treatment. Stock solution of DCA (SIGMA
St. Louis, MO) was prepared in distilled water and directly applied
to astrocyte monolayers at the indicated concentrations. For co-
culture experiments, astrocyte monolayers were treated with DCA
for 24 h and motor neurons were plated in fresh L15
supplemented media, after washing twice with Dulbecco’s
phosphate buffered saline (DPBS). Motor neuron survival was
assessed after 48 h by directly counting all p75 immunoreactive
cells displaying neurites longer than 4 cell bodies in diameter [53].
Proliferation assessment
Confluent astrocyte cultures were incubated with 10 mg/ml
bromo deoxyuridine (BrdU) and 5 mM DCA or vehicle in
DMEM 2% FBS for 24 h. Cells were fixed in 4% paraformal-
dehyde, incubated in 1 N HCl for 1 h and immunofluorescence to
detect BrdU using 1:300 diluted mouse monoclonal antibody
(Dako) was performed. Alexa Fluor
488 conjugated goat anti-mouse
(Invitrogen) was used as secondary antibody, and propidium
iodide to counterstain total nuclei. At least 600 nuclei were
counted for each point. Proliferation is expressed as the percentage
of BrdU immunoreactive nuclei with respect to total propidium
iodide stained nuclei.
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Cells were treated with DCA as described above. After 24 h of
treatment, proteins were extracted from cells in 1% SDS
supplemented with 2 mM sodium orthovanadate and Cømplete
protease inhibitor cocktail (Roche). Lysates were resolved by
electrophoresis on 12% SDS-polyacrylamide gels and transferred
to a polyvinylidene fluoride membrane (PVDF; Thermo). The
membrane was blocked for 1 h at room temperature in 5%
skimmed milk in TBS-T (Tris-buffered saline with 0.1% Tween).
The membrane was then probed overnight with primary antibodies
in 1% skimmed milk in TBS-T at 4uC, washed in TBS-T, and then
probed with the appropriate horseradish peroxidase (HRP)-
conjugated secondary antibody for 60 min at room temperature.
Primary antibodies were rabbit polyclonal phosphodetect anti-
PDH-E1a(pSer
293) 1:500 (AP1062; Calbiochem) and mouse
monoclonalanti-PDHE1a 1:750 (#456600, Invitrogen). Secondary
antibodies were anti-rabbit (1:2500) and anti-mouse (1:5000) HRP
conjugates (Thermo). Proteins were visualized with ECL western
blotting substrate (Pierce Biotechnology). b-actin was used as a
loadingcontrol.Densitometricanalysiswasperformedusing ImageJ
software. The relative levels of pSer
293 E1a and total E1a were
quantified. The pSer
293 to total E1a ratio was calculated and
normalized against vehicle-treated non Tg mice.
Histological analysis and immunofluorescence
Transgenic and non-transgenic mice groups (n=3 per group)
were treated as described above, from 70 days of age. After 20 days,
mice were transcardially perfused with 4% paraformaldehyde
fixative in DPBS under deep anesthesia (pentobarbital, 50 mg/kg
i.p.). The lumbar spinal cords were postfixed and embedded in
paraplast. 5 mm-thick, serial sections were stained with toluidine
blue or processed for immunofluorescence. For GFAP immunode-
tection, sections were permeabilized (0.2% Triton X-100 in PBS)
and unspecific binding blocked (10% goat serum, 2% BSA, 0.2%
Triton X-100 in DPBS), incubated with primary antibody (mouse
monoclonal Cy-3 conjugated anti-GFAP; 1:600, Sigma) overnight,
and mounted with glycerol. Images were obtained using an
Olympus IX81 epifluorescence microscope.
Assessment of motor neuron number and astrogliosis in
the lumbar spinal cord
The number of motor neurons was assessed by counting every
cell on lamina IX of Rexed displaying motor neuron morphology
with nucleus and nucleolus on every fifth toluidine blue stained
5 mm section (at least 25 sections per animal) through the lumbar
spinal cord.
Quantification of astrogliosis was performed on images obtained
from every fifth GFAP immunostained section (20 sections from
each group) using ImageJ software (NIH). Ventral horn area
occupied by GFAP immunofluorescence was measured and
expressed as a percentage of total ventral horn area in each section.
Oxygen consumption
Oxygen consumption studies were performed either on spinal
cord tissue or in astrocyte monolayers. Tissue or cell respiration
was evaluated using Oxygraph 2 K (Oroboros Instruments Corp).
Oxygen consumption was recorded at 37uC in intact cells or spinal
cord tissue. The rate of oxygen consumption was calculated by
means of the equipment software (DataLab) and was expressed as
pmol of O2?s
21?ml
21.
For cell respiration, astrocyte monolayers were treated with
DCA (0.5 and 5 mM) or vehicle for 24 h. Then, astrocytes were
scraped and resuspended at 2610
6 cells/ml in culture medium.
Mitochondrial oxygen consumption and RCR (respiratory control
ratio) was calculated as: RCR=maximum uncoupled flux
(FCCP)2(antimycin A-inhibited flux)/(oligomycin-inhibited
flux)2(antimycin A-inhibited flux) of intact cells respiring, oxygen
consumption after addition of 2 mg/ml oligomycin, 0.5 mM steps of
FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone and
followed by 2.5 mM antimycin A respectively as described [54].
For spinal cord studies 70 day-old mice were treated with DCA
or vehicle for 20 days (n=3 per group). Then, immediately
following sacrifice, lumbar spinal cords were dissected. Spinal cord
samples were immediately rinsed in respiration medium (Sucrose
110 mM, Mops 60 mM, EGTA 0.5 mM, BSA 1 g/l, MgCL2
3 mM, KH2PO4 10 mM, HEPES 20 mM, pH 7,1) and set in the
Oroboros oxygraph for high resolution respirometry. Mitochon-
drial oxygen consumption was measured as indicated in cell
studies.
Grip strength measurements
Motor function was tested with a Grip Strength Meter (San
Diego Instruments, San Diego CA). Tests were performed by
allowing the animals to grasp the platform with both hind limbs,
followed by pulling the animals until they released the platform.
The force measurement was recorded twice a week from week 6
(baseline) until death in four separate trials.
Neuromuscular junction measurements
The extensor digitorum longus (EDL) and the soleus muscles
from the same animals used for oxygen consumption studies were
dissected immediately after sacrifice. Muscles were immersed for
60 minutes in 0.5% paraformaldehyde in DPBS, rinsed with
DPBS (three times, 15 minutes each) and mechanically dissociated
into small bundles of fibers using fine forceps under a
stereomicroscope. The teased fibers were incubated with a
blocking buffer containing 50 mM glycine, 1% BSA and 0.5%
Triton X-100 for at least 3 hours and then in tetramethylrhoda-
mine-conjugated a-bungarotoxin (TMR-BgTx) (T0195 Sigma;
1:1500 in blocking buffer) overnight (ON) at 4uC. After washing
(three times, 20 minutes each) under agitation with PBS, fibers
were left ON at 4uC in glycerol-Tris pH 8.8 (4:1) which was used
as mounting medium for all the preparations.
Image acquisition and quantitative image processing: the teased
fiber preparations were observed by epifluorescence using an
Olympus IX81 microscope. For each EDL muscle the images of
15–35 neuromuscular junctions were taken and stored for later
analysis using Adobe Photoshop software. The total area, defined
as the area delimited by the external outline of the TMR-BgTx -
stained endplate marked with the Lasso tool, including both
stained and non-stained areas was measured. The resulting
numbers of selected pixels were counted with the Histogram tool.
Data were expressed as percentage of neuromuscular junction
total area from non transgenic control animals.
Statistics
Survival curves were compared by Kaplan-Meier analysis with
the Log-rank test using Sigmaplot 12 (Systat software). All culture
assays were performed in duplicate and each experiment was
repeated at least three times. Quantitative data were expressed as
mean 6 SEM and ANOVA and Student’s t test were used for
statistical analysis, with p,0.05 considered significant. When the
normality test failed, comparison of the means was performed by
one-way ANOVA on ranks followed by the Kruskal–Wallis test.
Data from GFAP were analyzed using a one-way ANOVA and
compared by all pairwise multiple comparison procedures (Holm-
Sidak method). All statistics computations were performed using
DCA Effects in ALS Models
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e34776the Sigma Stat System (1994, Jandel Scientific, San Rafael, CA,
USA), or GraphPad InStat software, version 3.06.
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